BridgeMD
Compares treatment options for Glaucoma
Official title Rocklatan vs Latanoprost Post-DSLT
ClinicalTrials.gov ID: NCT07465913
What this study is testing
What is Rocklatan 0.02%-0.005% Ophthalmic Solution?
Rocklatan 0.02%-0.005% Ophthalmic Solution is an investigational medicine, being studied as a potential treatment for glaucoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG).
- On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog.
- Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes.
- Best-corrected visual acuity (BCVA) ≥20/60 in both eyes.
- Ability and willingness to provide informed consent.
You likely can't join if
- Ocular hypertension only (no glaucomatous damage).
- Inability or medical ineligibility for washout of ocular hypotensive medications.
- Prior selective laser trabeculoplasty (SLT) within 12 months of screening.
- History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery [MIGS] affecting outflow).
- Narrow or closed angles with gonioscopy (Shaffer grading ≤2).
- Active ocular infection, uveitis, or severe dry eye.
See the full eligibility criteria
- Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG).
- On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog.
- Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes.
- Best-corrected visual acuity (BCVA) ≥20/60 in both eyes.
- Ability and willingness to provide informed consent.
- Ocular hypertension only (no glaucomatous damage).
- Inability or medical ineligibility for washout of ocular hypotensive medications.
- Prior selective laser trabeculoplasty (SLT) within 12 months of screening.
- History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery [MIGS] affecting outflow).
- Narrow or closed angles with gonioscopy (Shaffer grading ≤2).
- Active ocular infection, uveitis, or severe dry eye.
- Corneal pathology interfering with IOP measurement.
- Advanced glaucoma (threat to fixation).
- Known hypersensitivity to Rocklatan, latanoprost, or study medication components.
- Pregnancy or lactation.
The study team makes the final eligibility decision.
Where it's taking place
- Beaumont, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beaumont, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.